UBS released a statement on Esperion Therapeutics Inc (NASDAQ: ESPR) after its analysis of the opportunity and likely utilization of lead program ETC-1002 in hypercholesterolemia. UBS initiated coverage on Esperion, rating the company as a Buy with a $140 price target.
Analysts at UBS wrote, "The drug appears well-positioned to address a potentially large number of patients, yet our outlook implies conservative assumptions on adoption and potential competitors."
Although shares are up 129 percent year-to-date, UBS still highlights the potential revenue opportunity based on the drug program. Based on trial results, this catalyst may bring more value to the stock over the next 12 months.
Related Link: Barclays Raises Biogen Forecasts After Physician Survey
Shares of Esperion Therapeutics closed Tuesday at $92.60. Shares were up more than 4 percent at $96.50 in Wednesday's pre-market session.
As noted above, shares have gained $52 in 2015.
Latest Ratings for ESPR
| Apr 2015 | UBS | Initiates Coverage on | Buy | |
| Mar 2015 | Citigroup | Assumes | Buy | |
| Feb 2015 | Stifel Nicolaus | Maintains | Buy |
View More Analyst Ratings for ESPR
View the Latest Analyst Ratings
See more from Benzinga
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.